Acta Medica Okayama volume74 issue2
2020-04 発行

The Efficacy of Mirabegron for the Relief of Ureteral Stent-Related Symptoms

Otsuki, Hideo Department of Urology, Abiko Toho Hospital
Yamasaki, Tomoya Department of Urology, Abiko Toho Hospital
Hori, Shunsuke Department of Urology, Abiko Toho Hospital
Aoki, Hiroshi Department of Urology, Abiko Toho Hospital
Kosaka, Takeo Department of Urology, Keio University
Uehara, Shinya Department of Urology, Kawasaki Medical School General Medical Center
Fujio, Kei Department of Urology, Abiko Toho Hospital
Publication Date
To investigate the efficacy of mirabegron for lower urinary tract symptoms in patients with an indwelling ureteral stent after ureterorenoscopic lithotripsy. This was a prospective follow-up study of 76 patients with stent-related symptoms (SRSs). Patients with upper urinary calculi who were pre-stented for > 2 weeks before lithotripsy were examined for the presence of SRSs by tests including the International Prostate Symptom Score (IPSS), OAB Symptom Score (OABSS), and urinary bother and pain measured by a Visual Analogue Scale (VAS) before lithotripsy. Mirabegron (50 mg/day) was prescribed post-lithotripsy for 2 weeks. SRSs were assessed at the time of stent removal. The IPSS scores improved significantly from 16.2 to 14.3 (p<0.001) and the IPSS-QoL scores decreased significantly from 5.0 to 4.6 (p=0.012). The OABSS scores improved significantly from 7.7 to 6.8 (p=0.006), and the urinary urgency scores (OABSS-Q3) decreased significantly from 3.24 to 2.68 (p<0.001). The number of nocturia episodes decreased significantly from 2.5 to 2.2 (p=0.045). Urinary bother and pain assessed by the VAS declined from 4.2 and 3.1 to 3.8 (p=0.15) and 2.5 (p=0.075), respectively. Mirabegron significantly improved SRSs and the number of nocturia episodes due to a ureteral stent.
Document Type
Original Article
stent-related symptoms
overactive bladder
ureterorenoscopic lithotripsy
ureteral stent
Link to PubMed
Thumnail 74_2_145.pdf 1.96 MB